News

Priority review is granted to a pharmaceutical compound that addresses an unmet medical need and would be a significant improvement in treatment compared to existing therapies. The FDA

The publication, “The Value of Medicines: Facts and Figures 2006,” compiles facts, trends and data that shows how prescription medicines are helping to improve the quality of healthcare

This study was cleared to begin following the successful completion of a phase Ia study that confirmed the bio-availability of NV-52 in oral form, and its safety when

Alprox-TD is based on NexMed’s proprietary NexACT drug delivery technology, which the company has also used to develop a number of experimental medicines, including treatments for nail fungus

AB-1001 is designed to deliver a commercially available 5HT3-antagonist through the skin for a continuous period of up to five days, thereby providing the patient with sustained relief

Aggrastat (tirofiban hydrochloride), a glycoprotein (GP) IIb/IIIa inhibitor, is used for the treatment of acute coronary syndromes, including unstable angina and non-Q-wave myocardial infarction. Developed by Merck, Aggrastat

The ongoing IoGen study is being conducted at over 25 active sites across the US. Symbollon is planning to conduct a comprehensive advertising campaign during the remainder of

The study, results of which were published in the New England Journal of Medicine, was conducted in the Intramural Research Program of the US National Institute of Arthritis

The results are published in the journal Antimicrobial Agents and Chemotherapy, in a paper authored by AVI research scientists Dr Bruce Geller and Lucas Tilley. Highlights from the